Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery

Sponsor
Centre Hospitalier Universitaire de Nice (Other)
Overall Status
Terminated
CT.gov ID
NCT00823576
Collaborator
(none)
64
1
2
26.9
2.4

Study Details

Study Description

Brief Summary

Because local anesthetic infiltration has not been comparated to continuous infusion after spine fusion surgery, the investigators designed this study to determine whether this technique could enhance analgesia and improve patient outcome after posterior lumbar arthrodesis.

The Main Objective of the study is to compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving an infiltration "single shot" of local analgesic (Ropivacaïne), one receiving a single shot infiltration and a continuous infiltration of Ropivacaine during 48 hours.

In both groups the wound was infiltrated with a solution of ropivacaine 0.5% 200 mg/40 mL, and in one group an infusion of ropivacaine 0.2% 5 mL/h was maintained for 48 h.

The secondary outcomes are the consumption of morphine,the rate of the nausea and the postoperative vomits, the delay up to the first rise, the quality of the sleep, the duration of hospital stay and the persistence of residual pain.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Postoperative pain after posterior lumbar stabilization surgery is related to soft tissue and muscle dissection and to manipulations and removal at the operation site. Most patients complain of severe pain at rest during the first 24 h after surgery. This pain increases considerably with mobilization because of the reflex spasm of paraspinal muscles that is triggered by the primary wound pain. During the following 48-72 h, postoperative back pain is generally moderate at rest, whereas it remains severe on movement and produces discomfort that can interfere with patient mobilization and, possibly, with discharge time. Despite the favourable effects of analgesia in the early postoperative period, this drug association may produce a number of well-known side effects, such as nausea, vomiting, respiratory depression, sedation, renal abnormality, and upper gastrointestinal and operative site bleeding. Local anesthetic infiltration of the surgical wound is a useful method in the treatment of postoperative pain after various surgical procedures. Ropivacaine is an interesting molecule for infiltration because of its vasoconstrictive properties and decreased neuro- and cardiotoxicity compared with bupivacaine.

The Main Objective of the study is to compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving an infiltration "single shot" of local analgesic (Ropivacaïne), one receiving a single shot infiltration and a continuous infiltration of Ropivacaine during 48 hours.

After we obtained approval from the ethics committee and informed, written consent from patients, patients older than 18 years old , heavier than 50 kg, without psychological disorders, benefiting from of arthrodesis scheduled by a rachis lumbar posterior way were enrolled.

Patients were randomized to one of the two following postoperative analgesia groups after a presealed envelope was opened.

Post operative pain management is standardised with paracetamol, profenid and ACP morphine for each patient.

In both groups the wound was infiltrated with a solution of ropivacaine 0.5% 200 mg/40 mL, and in one group an infusion of ropivacaine 0.2% 5 mL/h was maintained for 48 h.

The Main Objective of the study is to compare the pain between 2 groups by means of the EVA (score of 0 for absence of pain in 10 for conceivable maximal pain) measured at H2, H8, H16, H24, H48.

The secondary outcomes are:
  • The consumption of morphine 24 H and 48 H after surgery - The rate of the nausea and the postoperative vomits defined as the number of patients presenting the symptom on the number of patients in the group. - Delay up to the first rise

  • Delay will be estimated in hours enter the end of the intervention surgery and the first one night

  • The quality of the sleep estimated every morning with an analogical visual scale from 0 (very bad quality of sleep) to 10 (excellent quality of sleep)

  • The duration of stay: calculated in days as the delay between the end of the intervention and the capacity at the exit.

  • Recall of the patients in 3 and 6 months after the surgery to estimate the persistence of residual pains and if they still consume opioid. We shall ask to the patient to clarify the presence or the absence of pain The amount of analgesics required and the local and systemic adverse events were recorded for each patient.

Discharge was decided by the surgeons according to the following discharge criteria:1) satisfactory pain control for self-mobility; 2) uncomplicated wound-healing process 3) no impairments in haemoglobin 4) normothermie 5) normal transit, no nausea and vomit.

Sample-size calculation was based on an expected difference of 20 mm in VAS measurements for pain between groups. We calculate we need 64 patients for our main outcome. Each patient will be monitored during 6 month after the surgery.

The length of the study is 2 years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery
Study Start Date :
Dec 1, 2008
Actual Primary Completion Date :
Dec 1, 2010
Actual Study Completion Date :
Mar 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

Group witness: one receiving a single bolus of analgesic Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it

Drug: Ropivacaine
Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.

Active Comparator: 2

Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.

Drug: Ropivacaine
Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.

Outcome Measures

Primary Outcome Measures

  1. Primary end points Principal: We compare the pain between 2 groups by means of the EVA (score of 0 for absence of pain in 10 for conceivable maximal pain) measured at H2, H8, H16, H24, H48. [2 days]

Secondary Outcome Measures

  1. The consumption of morphine mg-The rate of the nausea and the postoperative vomits defined-Delay up to the first rise-Delay will be estimated in hours enter the end of the intervention surgery and the first one night [2 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients benefiting from of arthrodesis scheduled by a rachis lumbar posterior way

  • Older than 18 years old

  • Heavier than 50 kg

  • Patients in the state health scheme

  • Patients having signed consent

Exclusion Criteria:
  • Surgery linked to an infectious, tumoral or traumatological cause

  • Patients suffering of chronic pain define as patients consuming stage 3 analgesic since more than 3 months.- Patients receiving isoptine or flécaïne before surgery

  • Arthrodesis on more than 3 stages

  • Impossibility of cooperate with the patient

  • Contra-indication for the maintain or the installation of a catheter diffusing analgesic

  • Contra-indication of using local analgesic

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez Nice Alpes-Maritimes France 06001

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Nice

Investigators

  • Principal Investigator: LITRICO LS Stéphane, PH, CHU de Nice - Hôpital Pasteur - 30 ave de la Voie Romaine - 06100 Nice

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00823576
Other Study ID Numbers:
  • 08-CIR-03
First Posted:
Jan 15, 2009
Last Update Posted:
Jun 1, 2011
Last Verified:
Jan 1, 2009
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2011